Reported about 17 hours ago
Pfizer's recent landmark deal with the Trump administration to lower drug prices and boost U.S. manufacturing has sparked renewed interest in large pharmaceuticals. This agreement provides Pfizer with a three-year tariff exemption on imports in exchange for increased domestic investment, addressing major industry concerns about pricing and tariffs. Following the deal, stocks of major drug companies like Merck, Johnson & Johnson, Bayer, and Novartis have risen significantly, driven by improved investor sentiment and expectations of further partnerships similar to Pfizer's. The article discusses how each of these companies is positioned for growth amidst the sector recovery.
Source: YAHOO